Edwards Lifesciences Corp.’s Sapien M3 secured CE mark for its Sapien M3 mitral valve replacement system for transfemoral treatment of patients with mitral valve disease who are ineligible for surgery ...

The Irvine-based medical device maker today announced that it received CE mark approval for its Sapien M3 mitral replacement ...

Edwards’ device, dubbed Sapien M3, is the first approved system to use a transfemoral approach to treating mitral ...

Edwards Lifesciences (NYSE:EW) announced today that it received CE mark approval for its Sapien M3 mitral valve replacement ...

Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received ...